Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

This study is ongoing, but not recruiting participants.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group Identifier:
First received: October 3, 2003
Last updated: September 15, 2015
Last verified: September 2015